Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etokimab in moderate-to-severe atopic dermatitis
NCT03533751Phase 2Completed
- Sponsor
- AnaptysBio, Inc.
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of etokimab in atopic dermatitis (AD), sponsored by AnaptysBio, Inc.. Started Jun 2018; status: completed.
02
Drugs
etokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03533751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533751.